Abstract
Objective We explored whether a history of sleep disorder affected a current diagnosis of cognitive impairment and clinical conversion in a non-demented elderly population.Methods Comprehensive clinical data collected as part of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) was analyzed. A history of sleep disorder was recorded in the recent ADNI medical database. Standard clinical and neuropsychological tests were performed both at baseline and follow-up visit. Multiple logistic regression analysis was performed after adjusting for age, sex, education, apolipoprotein E ε4 status, vascular risk score, body mass index, Geriatric Depression Scale score, and use of sleeping pills.Results A total of 391 cognitively normal individuals, 303 with early mild cognitive impairment (MCI) and 364 with late MCI were included. Sleep disorder history was significantly associated with an increased risk of MCI but not with clinical conversion. A history of insomnia or obstructive sleep apnea (OSA) significantly increased the risk of MCI, but only an OSA history predicted progression to Alzheimer’s disease (AD) dementia.Conclusion Our findings suggest that a sleep disorder history usefully aids early detection of cognitive impairment and emphasize that such sleep disorder, particularly OSA, is important as potential target for AD prevention.
Funder
Hallym University Research
Alzheimer’s Disease Neuroimaging Initiative
Department of Defense Alzheimer’s Disease Neuroimaging Initiative
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
AbbVie
Alzheimer’s Association
Alzheimer’s Drug Discovery Foundation
Araclon Biotech
BioClinica, Inc.
Biogen
Bristol-Myers Squibb Company
CereSpir, Inc.
Cogstate
Eisai Inc.
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
EuroImmun
F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
Fujirebio
GE Healthcare
IXICO Ltd.
; Janssen Alzheimer Immunotherapy Research & Development, LLC.
; Johnson & Johnson Pharmaceutical Research & Development LLC.
Lumosity
Lundbeck
Merck & Co., Inc.
Meso Scale Diagnostics, LLC.
NeuroRx Research
Neurotrack Technologies
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Piramal Imaging
Servier
; Takeda Pharmaceutical Company
Transition Therapeutics
Canadian Institutes of Health Research
Foundation for the National Institutes of Health
Northern California Institute for Research and Education
Alzheimer’s Therapeutic Research Institute at the University of Southern California
Laboratory for Neuro Imaging at the University of Southern California
Publisher
Korean Neuropsychiatric Association
Subject
Biological Psychiatry,Psychiatry and Mental health